Alfasigma Secures Exclusive Rights from Innovative Molecules to Parenteral Adibelivir for Treatment of HSV Encephalitis, an Ultra-Rare Disease
January 13, 2026
Alfasigma S.p.A. (“Alfasigma”), a global pharmaceutical company, and Innovative Molecules GmbH (“Innovative Molecules”), a clinical-stage biotechnology company, today announced a strategic partnership whereby Alfasigma will invest in Innovative Molecules and has obtained the exclusive worldwide license to the parenteral formulation of adibelivir (formerly IM 250) for the treatment of Herpes Simplex Virus (HSV) encephalitis, an ultra-rare and life threatening condition.
